tiprankstipranks
Trending News
More News >

Xspray Pharma Reports Q1 2025 Results and Advances in Drug Development

Story Highlights
Xspray Pharma Reports Q1 2025 Results and Advances in Drug Development

Confident Investing Starts Here:

The latest update is out from Xspray Pharma AB ( (SE:XSPRAY) ).

Xspray Pharma reported its Q1 2025 financial results, highlighting a net sales figure of SEK 0 thousand and a loss before tax of SEK -42,321 thousand. Significant developments included the re-submission of the market approval application for Dasynoc® to the FDA and positive interim data from a study on XS003 nilotinib, demonstrating stable bioavailability. These advancements underscore the potential impact of Xspray’s technology on patient care and its strategic positioning in the oncology drug market.

More about Xspray Pharma AB

Xspray Pharma AB operates in the pharmaceutical industry, focusing on developing improved versions of existing drugs using its proprietary HyNap™ technology platform. The company primarily targets the oncology market with its lead product candidates, including Dasynoc® and XS003 nilotinib.

Average Trading Volume: 19,600

Current Market Cap: SEK1.05B

Find detailed analytics on XSPRAY stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App